146 related articles for article (PubMed ID: 8072943)
1. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo.
Abdel-Naser MB; Krüger-Krasagakes S; Krasagakis K; Gollnick H; Abdel-Fattah A; Orfanos CE
Pigment Cell Res; 1994 Feb; 7(1):1-8. PubMed ID: 8072943
[TBL] [Abstract][Full Text] [Related]
2. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.
Norris DA; Kissinger RM; Naughton GM; Bystryn JC
J Invest Dermatol; 1988 Jun; 90(6):783-9. PubMed ID: 3373009
[TBL] [Abstract][Full Text] [Related]
3. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes.
Li YL; Yu CL; Yu HS
J Invest Dermatol; 2000 Dec; 115(6):969-73. PubMed ID: 11121127
[TBL] [Abstract][Full Text] [Related]
4. Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.
Le Poole IC; Stennett LS; Bonish BK; Dee L; Robinson JK; Hernandez C; Hann SK; Nickoloff BJ
Br J Dermatol; 2003 Oct; 149(4):739-48. PubMed ID: 14616364
[TBL] [Abstract][Full Text] [Related]
5. Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo.
Tulic MK; Cavazza E; Cheli Y; Jacquel A; Luci C; Cardot-Leccia N; Hadhiri-Bzioueche H; Abbe P; Gesson M; Sormani L; Regazzetti C; Beranger GE; Lereverend C; Pons C; Khemis A; Ballotti R; Bertolotto C; Rocchi S; Passeron T
Nat Commun; 2019 May; 10(1):2178. PubMed ID: 31097717
[TBL] [Abstract][Full Text] [Related]
6. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo.
Yu HS; Chang KL; Yu CL; Li HF; Wu MT; Wu CS; Wu CS
J Invest Dermatol; 1997 Apr; 108(4):527-9. PubMed ID: 9077486
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis of melanocytes in vitiligo results from antibody penetration.
Ruiz-Argüelles A; Brito GJ; Reyes-Izquierdo P; Pérez-Romano B; Sánchez-Sosa S
J Autoimmun; 2007 Dec; 29(4):281-6. PubMed ID: 17888626
[TBL] [Abstract][Full Text] [Related]
8. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.
Le Poole IC; van den Wijngaard RM; Westerhof W; Das PK
Am J Pathol; 1996 Apr; 148(4):1219-28. PubMed ID: 8644862
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
[TBL] [Abstract][Full Text] [Related]
10. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients.
Hann SK; Kim HI; Im S; Park YK; Cui J; Bystryn JC
J Dermatol Sci; 1993 Dec; 6(3):201-5. PubMed ID: 8136318
[TBL] [Abstract][Full Text] [Related]
11. Melanocytes are not absent in lesional skin of long duration vitiligo.
Tobin DJ; Swanson NN; Pittelkow MR; Peters EM; Schallreuter KU
J Pathol; 2000 Aug; 191(4):407-16. PubMed ID: 10918216
[TBL] [Abstract][Full Text] [Related]
12. Cytolytic antibodies to melanocytes in vitiligo.
Cui J; Arita Y; Bystryn JC
J Invest Dermatol; 1993 Jun; 100(6):812-5. PubMed ID: 8496621
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a complement-mediated inhibition and an antibody-dependent cellular cytotoxicity of dermal fibroblasts in alopecia areata.
Abdel-Naser MB; Blume-Peytavi U; Abdel-Fatah A; Orfanos CE
Acta Derm Venereol; 1994 Sep; 74(5):351-4. PubMed ID: 7817669
[TBL] [Abstract][Full Text] [Related]
14. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo.
Austin LM; Boissy RE; Jacobson BS; Smyth JR
Clin Immunol Immunopathol; 1992 Aug; 64(2):112-20. PubMed ID: 1643744
[TBL] [Abstract][Full Text] [Related]
15. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo.
Tembhre MK; Sharma VK; Sharma A; Chattopadhyay P; Gupta S
Clin Chim Acta; 2013 Sep; 424():27-32. PubMed ID: 23680073
[TBL] [Abstract][Full Text] [Related]
16. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
[TBL] [Abstract][Full Text] [Related]
17. Vitiliginous vs pigmented skin response to intradermal administration of interferon gamma.
Gilhar A; Aizen E; Ohana N; Etzioni A
Arch Dermatol; 1993 May; 129(5):600-4. PubMed ID: 8097622
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris.
Kotobuki Y; Tanemura A; Yang L; Itoi S; Wataya-Kaneda M; Murota H; Fujimoto M; Serada S; Naka T; Katayama I
Pigment Cell Melanoma Res; 2012 Mar; 25(2):219-30. PubMed ID: 22136309
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
Li DG; Hu WZ; Ma HJ; Liu W; Yang QQ; Zhao G
Mol Med Rep; 2016 Aug; 14(2):1275-82. PubMed ID: 27277530
[TBL] [Abstract][Full Text] [Related]
20. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi.
van Geel NA; Mollet IG; De Schepper S; Tjin EP; Vermaelen K; Clark RA; Kupper TS; Luiten RM; Lambert J
Pigment Cell Melanoma Res; 2010 Jun; 23(3):375-84. PubMed ID: 20370855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
